EMN 2021 | Early relapse prediction in myeloma treated with novel agents
Alessandro Gozzetti, MD, PhD, Azienda Ospedaliera Universitaria Senese, Siena, Italy, gives an overview of the predictors of early relapse in transplant-eligible multiple myeloma patients who are treated with novel agents. In particular, Prof. Gozzetti highlights the prognostic use of measurable residual disease (MRD), as assessed by next generation flow, to predict response to monoclonal antibodies. This approach was demonstrated in the MAIA study (NCT02252172) investigating daratumumab, lenalidomide and dexamethasone versus lenalidomide and dexamethasone as first-line therapy in patients with multiple myeloma. This interview took place during the 2021 European Myeloma Network (EMN) congress.
Disclosures
Alessandro Gozzetti, MD, PhD, has received research funding from Janssen and Cilag Spa.
